Journal of neurology
-
Journal of neurology · Oct 2021
Observational StudyThe impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
To evaluate the frequency and headache-related impact response to monoclonal antibodies against calcitonin gene-related peptide (CGRP) in a clinical sample of refractory migraine patients. ⋯ In real-world clinical practice, monoclonal antibodies against CGRP proved to be effective treatments in resistant migraine patients.